SJM — The J. M. Smucker Company

Sentiment is mixed as of 2026-09-13. Analysts lean constructive after Q1 FY27 beat consensus on 2026-08-26, management raised FY27 adjusted EPS guidance to $10.50-$11.00, FCF outlook to ~$1.1B, and leverage hit the 2.9x net debt/EBITDA target; several firms raised price targets. But the stock had fallen 3.92% in the prior week, sat 3.59% below its 20-day SMA with RSI at 43.26, so near-term price action does not confirm the bullish narrative.

Revenue growth has been modestly reaccelerating: Q1 FY27 revenue of $2.219B was up 5.0% YoY versus Q1 FY26's $2.113B; Q4 FY26 rose 5.8% YoY, Q3 FY26 rose 7.0%, and Q2 FY26 rose 2.6%. Operating margins have recovered sharply from impairment-depressed quarters: Q1 FY27 operating margin was 23.1%, Q4 FY26 19.8%, Q3 FY26 17.9%, and Q2 FY26 18.2%, versus Q1 FY26's 2.4% and negative margins in several FY25 quarters. Reported net income remains volatile because of large non-cash charges: Q3 FY26 net income was -$724.2M and Q4 FY25 was -$729.0M, dragging TTM EPS to $2.149. Free cash flow is the cleaner signal: TTM FCF through 2026-07-31 was roughly $1.59B, with Q1 FY27 FCF of $337.3M. The trend is improving underlying operations, not structural deterioration, but reported earnings optics remain noisy.

On trailing numbers SJM looks expensive: 56.3x TTM P/E on $2.149 TTM EPS, versus a 19.77x 5-year average P/E. But that trailing P/E is distorted by non-cash impairment/loss charges. Forward valuation is much more reasonable: the $10.79 next-FY consensus EPS implies about 11.2x forward P/E at $121.14. P/S is 1.414x versus a 5-year average of 1.57x, so the stock is not rich on sales. The deterministic valuation context labels it 'Rich vs. its own history' because of the trailing P/E distortion, but on normalized forward earnings the stock screens cheap-to-fair, tempered by leverage and low current ratio.

The market is pricing SJM at roughly 11.2x forward EPS of $10.79, well below the analyst consensus target of $137.29 (about 12.7x forward EPS) and far below the distorted trailing P/E. If management delivers the $10.50-$11.00 adjusted EPS guide and FCF recovers toward $1.1B, a modest re-rating to 13-14x forward EPS would imply $140-$151. The risk is that the market is already looking through the impairments and pricing in a recovery; if coffee deflation or consumer weakness pressures volumes, the forward EPS estimate could prove optimistic.

As of 2026-09-13, RSI was 43.26, price was 3.59% below the 20-day SMA, 0.86% above the 50-day SMA, and 13.04% above the 200-day SMA. The one-week return was -3.92%, while 1-month, 3-month, and 6-month returns were +1.98%, +3.99%, and +14.2%, respectively. This looks like a pullback within a longer uptrend rather than a breakdown, but RSI is not oversold. Better entry timing would come from a reclaim of the 20-day SMA or an RSI move toward 30.

• Stabilizing interest rates reduce debt-servicing risk and help SJM's deleveraging story after reaching 2.9x net debt/EBITDA ahead of schedule.
• Commodity cost volatility, especially green coffee pricing, remains a swing factor: coffee deflation can pressure reported revenue but may help gross margins if pricing catches up.
• Value-seeking consumer behavior and private-label substitution continue to pressure packaged-food volumes and pricing power.
• Tariff and trade policy uncertainty can affect input costs; Q1 FY27 benefited from tariff refunds, which may not repeat.
• Defensive consumer staples can outperform in slowing economies but may lag if markets rotate toward more cyclical or rate-sensitive sectors.

• Q2 FY27 earnings in late November 2026, with focus on whether Uncrustables, Café Bustelo, Meow Mix, and Milk-Bone sustain positive volume growth.
• Further progress on deleveraging and potential portfolio actions, including divestitures or bolt-on M&A.
• Continuation of the 25-year dividend growth streak after the July 2026 increase to $1.12 quarterly.
• Coffee cost deflation and pricing actions that could either pressure revenue or support margins.
• Multiple re-rating if impairments prove non-recurring and forward EPS converges toward guidance.

• Continued or new impairment charges, especially if acquired brands or pet assets underperform.
• Weak consumer spending and private-label competition could pressure volumes and pricing.
• Coffee commodity cost volatility and difficulty passing through price increases.
• High leverage and weak liquidity: D/E of 1.199, current ratio of 0.87, and quick ratio of 0.352.
• Execution risk on growth brands; missing FY27 adjusted EPS guidance of $10.50-$11.00 would undermine the forward valuation case.

The fixed score/valuation mapping forces a Bearish lean, but my independent read is more constructive than that label suggests. Trailing earnings are heavily distorted by non-cash charges, while forward P/E is about 11.2x, FCF yield is strong, and the dividend looks covered. Still, leverage and low liquidity mean I would want evidence that volume growth and margin recovery are durable before underwriting a re-rating.

I applied a 13.5x multiple to next-FY consensus EPS of $10.79, which yields $145.67. That multiple is a discount to SJM's 19.77x 5-year average P/E but a premium to the distorted 56x trailing P/E and the current 11.2x forward P/E, reflecting normalized earnings power, strong free cash flow, and the 3.64% dividend yield.